#United States #New York #Pomerantz LLP #SEC Investigation #Capricor Therapeutics

Investor Alert: Pomerantz Law Firm Investigates Claims on Behalf of Capricor Therapeutics Investors

Pomerantz LLP, a prominent law firm known for its expertise in securities litigation, has undertaken an investigation concerning potential securities fraud related to Capricor Therapeutics, Inc. (NASDAQ: CAPR). The firm seeks to represent investors who may have suffered losses due to unlawful business practices or misleading information from the company.

Background on Capricor Therapeutics

Founded with the mission to innovate in the biotechnology sector, Capricor Therapeutics focuses on developing cutting-edge therapies, particularly targeted at treating Duchenne muscular dystrophy (DMD). The company has been working on its leading product, deramiocel, which is positioned as a treatment for patients suffering from DMD-related cardiomyopathy. Recent developments and announcements have piqued investor interest, but concerns have arisen following significant shifts in the company’s stock performance.

Recent Events Leading to Investigation

In May 2025, Capricor released a statement indicating that the U.S. Food and Drug Administration (FDA) would be conducting an advisory committee meeting regarding its Biologics License Application (BLA) for deramiocel. This announcement initially boosted investor optimism; however, the following day saw a drastic drop in share price, which fell by $3.00 per share or 29.13%, closing at $7.30. The decline raised eyebrows among investors and analysts alike.

Further compounding these issues, on June 20, 2025, the publication STAT reported that the FDA had canceled the much-anticipated advisory committee meeting due to uncertainties surrounding the drug's efficacy and safety profile. Following this revelation, Capricor's stock experienced another substantial hit, falling by $3.68 per share, amounting to a staggering 30.82% drop, which saw shares close at $8.26 on that day.

With such rocky developments and volatility in stock prices, the investigation initiated by Pomerantz raises critical questions about the transparency and integrity of information disseminated by Capricor to its investors. Investors who feel they may have been misled or suffered financial losses are encouraged to contact Danielle Peyton at Pomerantz LLP to discuss their situation, as participation in a potential class action may be available.

The Role of Pomerantz LLP

Pomerantz LLP has a longstanding reputation in the legal arena, particularly regarding corporate misconduct and securities class actions. Founded by navigator Abraham L. Pomerantz, the firm has remained an influential advocate for investors, recovering millions in securities class action settlements. Their commitment to justice in the sphere of securities fraud indicates a robust support system for affected investors.

The firm has offices in major cities like New York, Chicago, Los Angeles, London, and Tel Aviv, showcasing its international reach and expertise in handling complex securities issues.

Pomerantz aims to ensure that those impacted by the alleged misconduct of Capricor Therapeutics can seek appropriate remedies for their financial setbacks. Their investigation not only seeks accountability but also aims to protect the broader investor community from future fraudulent practices.

Conclusion and Call to Action

For those who have invested in Capricor Therapeutics and have experienced losses due to the events surrounding the company’s FDA dealings, now is the time to act. Pomerantz LLP stands ready to guide and support you through the legal processes necessary to address these concerns. Please reach out to them via the contact information provided to learn more about your options and potential next steps.

To join this growing investigation or for more information regarding your investor rights, contact Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980.